UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 54

Sortiert nach

Castleman's Disease: From Basic Mechanisms to Molecular Therapeutics

The oncologist (Dayton, Ohio), 2011-01, Vol.16 (4), p.497-511

2011

Link zum Volltext

Verfügbarkeit prüfen

Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells

PloS one, 2017-09, Vol.12 (9), p.e0184922-e0184922

2017

Link zum Volltext

Verfügbarkeit prüfen

Histiocytic sarcoma as a secondary malignancy: pathobiology, diagnosis, and treatment

European journal of haematology, 2016-07, Vol.97 (1), p.9-16

2016

Link zum Volltext

Verfügbarkeit prüfen

Predictors for clinical benefit of immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis

Immunotherapy, 2019-02, Vol.11 (3), p.189-199

2019

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of Research Biopsies in Phase I Clinical Trials: The MD Anderson Cancer Center Experience

The oncologist (Dayton, Ohio), 2011-09, Vol.16 (9), p.1292-1298

2011

Link zum Volltext

Verfügbarkeit prüfen

Predictors of benefits from frontline chemoimmunotherapy in stage IV non-small-cell lung cancer: a meta-analysis

Oncoimmunology, 2019-12, Vol.8 (12), p.e1665974-e1665974

2019

Link zum Volltext

Verfügbarkeit prüfen

BRAF mutations in advanced cancers: clinical characteristics and outcomes

PloS one, 2011-10, Vol.6 (10), p.e25806-e25806

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3537: Cisplatin refractory lung cancer cells exhibit an increased autophagic flux at baseline and following exposure to cisplatin

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.3537-3537

2016

Link zum Volltext

Verfügbarkeit prüfen

Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data

Cancers, 2022-02, Vol.14 (4), p.1041

2022

Link zum Volltext

Verfügbarkeit prüfen

Rituximab-induced acute thrombocytopenia: an underappreciated entity

Leukemia & lymphoma, 2013-12, Vol.54 (12), p.2736-2737

2013

Link zum Volltext

Verfügbarkeit prüfen

A Novel High Content Imaging-Based Screen Identifies the Anti-Helminthic Niclosamide as an Inhibitor of Lysosome Anterograde Trafficking and Prostate Cancer Cell Invasion

PloS one, 2016-01, Vol.11 (1), p.e0146931

2016

Link zum Volltext

Verfügbarkeit prüfen

Correction: Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells

PloS one, 2018-05, Vol.13 (5), p.e0197016-e0197016

2018

Link zum Volltext

Verfügbarkeit prüfen

Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib

Pharmacogenomics and personalized medicine, 2015-01, Vol.8 (default), p.145-154

2015

Link zum Volltext

Verfügbarkeit prüfen

Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment

OncoTargets and therapy, 2016-01, Vol.9, p.5101-5116

2016

Link zum Volltext

Verfügbarkeit prüfen

Correction: A Novel High Content Imaging-Based Screen Identifies the Anti-Helminthic Niclosamide as an Inhibitor of Lysosome Anterograde Trafficking and Prostate Cancer Cell Invasion

PloS one, 2016-03, Vol.11 (3), p.e0151718-e0151718

2016

Link zum Volltext

Verfügbarkeit prüfen

Major Stressful Life Events and Risk of Developing Lung Cancer: A Case-Control Study

Clinical Medicine Insights. Oncology, 2019, Vol.13, p.1179554919835798-1179554919835798

2019

Link zum Volltext

Verfügbarkeit prüfen

Acute Promyelocytic Leukemia and Chronic Lymphocytic Leukemia: Concomitant Presentation of Two Molecularly Distinct Entities

The Journal of the Louisiana State Medical Society, 2017-05, Vol.169 (3), p.68

2017

Link zum Volltext

Verfügbarkeit prüfen

Ånaplastic Large-Cell Lymphoma With Leukemoid Reaction

Journal of clinical oncology, 2008-09, Vol.26 (26), p.4356-4358

2008

Link zum Volltext

Verfügbarkeit prüfen

Predictors of benefits to chemoimmunotherapy (CIT) in stage IV non-small-cell lung cancer (NSCLC): A meta-analysis

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e20595-e20595

2019

Link zum Volltext

Verfügbarkeit prüfen

Epigenetics in non-small cell lung cancer: from basics to therapeutics

Translational lung cancer research, 2016-04, Vol.5 (2), p.155-171

2016

Link zum Volltext

Verfügbarkeit prüfen

Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra)

Molecular cancer therapeutics, 2010-06, Vol.9 (6), p.1485-1488

2010

Link zum Volltext

Verfügbarkeit prüfen

Endobronchial Ultrasound for Nodal Staging of Patients with Non-Small-Cell Lung Cancer with Radiologically Normal Mediastinum. A Meta-Analysis

Annals of the American Thoracic Society, 2018-07, Vol.15 (7), p.864-874

2018

Link zum Volltext

Verfügbarkeit prüfen

Predictors of clinical benefit of checkpoint inhibitors-based immunotherapy in advanced non–small cell lung cancer: A meta-analysis

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e21121-e21121

2018

Link zum Volltext

Verfügbarkeit prüfen

KeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS8606-TPS8606

2022

Link zum Volltext

Verfügbarkeit prüfen

Exploratory biomarker analysis of the phase 3 KEYNOTE-604 study of pembrolizumab plus etoposide for extensive-stage SCLC

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.8503-8503

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 54

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(49)

Publikationsform

Sprache

Englisch
(53)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Castleman's Disease: From Basic Mechanisms to Molecular Therapeutics

Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells

Histiocytic sarcoma as a secondary malignancy: pathobiology, diagnosis, and treatment

Predictors for clinical benefit of immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis

Outcomes of Research Biopsies in Phase I Clinical Trials: The MD Anderson Cancer Center Experience

Predictors of benefits from frontline chemoimmunotherapy in stage IV non-small-cell lung cancer: a meta-analysis

BRAF mutations in advanced cancers: clinical characteristics and outcomes

Abstract 3537: Cisplatin refractory lung cancer cells exhibit an increased autophagic flux at baseline and following exposure to cisplatin

Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data

Rituximab-induced acute thrombocytopenia: an underappreciated entity

A Novel High Content Imaging-Based Screen Identifies the Anti-Helminthic Niclosamide as an Inhibitor of Lysosome Anterograde Trafficking and Prostate Cancer Cell Invasion

Correction: Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells

Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib

Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment

Correction: A Novel High Content Imaging-Based Screen Identifies the Anti-Helminthic Niclosamide as an Inhibitor of Lysosome Anterograde Trafficking and Prostate Cancer Cell Invasion

Major Stressful Life Events and Risk of Developing Lung Cancer: A Case-Control Study

Acute Promyelocytic Leukemia and Chronic Lymphocytic Leukemia: Concomitant Presentation of Two Molecularly Distinct Entities

Ånaplastic Large-Cell Lymphoma With Leukemoid Reaction

Predictors of benefits to chemoimmunotherapy (CIT) in stage IV non-small-cell lung cancer (NSCLC): A meta-analysis

Epigenetics in non-small cell lung cancer: from basics to therapeutics

Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra)

Endobronchial Ultrasound for Nodal Staging of Patients with Non-Small-Cell Lung Cancer with Radiologically Normal Mediastinum. A Meta-Analysis

Predictors of clinical benefit of checkpoint inhibitors-based immunotherapy in advanced non–small cell lung cancer: A meta-analysis

KeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer

Exploratory biomarker analysis of the phase 3 KEYNOTE-604 study of pembrolizumab plus etoposide for extensive-stage SCLC

Suchergebnisse filtern